Ketamine for Depression and Suicide Risk
NCT02094898
Completed
The purpose of this research study was to find out if the medication known as ketamine could help the symptoms of depression. This drug is approved by the U.S. Food and Drug Administration (FDA) as an anesthetic agent; however, it is not approved for use in depression treatment. The FDA allowed the use of this drug in this research study.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/10/2017
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Depression, Suicide
Register for Updates
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
NCT00516503
Completed
RATIONALE: Baclofen-amitriptyline-ketamine (BAK) gel may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether BAK gel is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy . PURPOSE: This randomized phase III trial is studying BAK gel to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2017
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +164 locations
Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Immunomodulatory Properties of Ketamine in Sepsis
NCT01089361
Completed
The aim of the study is to assess the effect of short-term infusion of ketamine at analgesic dosage on the immune response, morbidity and mortality among patients suffering from septic shock. We hypothesize that ketamine will modulate the cytokine response to sepsis and reduce morbidity and mortality.
Gender:
ALL
Ages:
Between 21 years and 100 years
Trial Updated:
07/21/2017
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Sepsis
Register for Updates
Ketamine For Acute Treatment of Pain in Emergency Department
NCT02306759
Completed
The aim of the study is to compare the safety \& efficacy of low dose ketamine and morphine versus morphine alone for acute generalized pain in the Emergency Department (ED). The investigators are also interested to investigate whether low-dose ketamine is a safe and effective alternative option to opioids for the acute treatment of pain in the Emergency Department. The agents that are available in the department includes acetaminophen, non-steroidal anti-inflammatory (NSAIDS) and opioids. In m... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/11/2017
Locations: The Brooklyn Hospital Center, Brooklyn, New York
Conditions: Pain
Register for Updates
Low Dose Ketamine as an Adjunct to Fentanyl in Outpatient Tonsillectomy
NCT00587665
Completed
Comparing patients receiving subanesthetic doses of Ketamine vs placebo to see if it can reduce narcotic needs for patients receiving a tonsillectomy and adenoidectomy
Gender:
ALL
Ages:
Between 3 years and 12 years
Trial Updated:
06/12/2017
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Pain
Register for Updates
Intranasal Ketamine Versus Intramuscular Ketamine for Procedural Sedation in Pediatric Patients
NCT01170247
Terminated
The purpose of this study is to determine if intranasal ketamine is equally as effective and safe as intramuscular ketamine for procedural sedation in pediatric patients.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
06/03/2017
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Sedation
Register for Updates
A Comparison of Intra-op Ketamine vs Placebo in Patients Having Spinal Fusion
NCT02424591
Completed
Postoperative pain is severe after major spine surgery. Opioids such as morphine and hydromorphone are routinely used for postoperative pain control. These drugs have significant side effects, most importantly respiratory depression, nausea, constipation and tolerance. Moreover, many spine surgery patients have used opioid pain medication for back pain long term, leading to pre-surgical opioid tolerance and increased postoperative pain. This has led to a search for adjuvant medications to reduce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2017
Locations: NYU School of Medicine, New York, New York
Conditions: Postoperative Pain
Register for Updates
Ketamine Versus Etomidate for Procedural Sedation for Pediatric Orthopedic Reductions
NCT00596050
Completed
There are multiple retrospective studies detailing the use of etomidate in pediatric procedural sedation but few to no prospective clinical trials. None have compared etomidate to ketamine, currently the most commonly used sedative in the emergency department for pediatric procedural sedation. The investigators propose a randomized, controlled trial comparing etomidate versus ketamine for procedural sedation for fracture reduction for children presenting with extremity fracture requiring sedatio... Read More
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
05/08/2017
Locations: St. Christopher's Hospital for Children, Philadelphia, Pennsylvania
Conditions: Conscious Sedation Failure During Procedure
Register for Updates
Peri-Operative Lidocane, Ketamine, or Lidocane and Ketamine Combination, Infusion for Patients Undergoing Spine Surgery
NCT01983020
Completed
This study has been designed as a controlled clinical trial to evaluate the efficacy of brief lidocaine infusion, brief ketamine infusion and a lidocaine/ketamine combined infusion when added to conventional opioid therapy following major spine surgery, as well as to evaluate the effects of the lidocaine/ketamine pain protocol on the feasibility of performing routine intraoperative neurophysiology during spine surgery in adults and determine whether this infusion protocol is compatible with intr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2017
Locations: Beth Israel Medical Center, New York, New York
Conditions: Postoperative Pain
Register for Updates
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression
NCT01260649
Terminated
Electroconvulsive therapy (ECT), is considered the most effective treatment for severe treatment resistant major depressive disorder (MDD), but it requires about 3 weeks of treatments and can cause considerable acute deficits in memory. It would be a major advance in treatment if ECT could work faster with fewer treatments and result in decrease incidence of memory problems. Ketamine is an excellent candidate for augmentation of ECT because of its acute effects on depression, its short half-life... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2017
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates
Ketamine Infusion for Treatment-resistant Major Depressive Disorder
NCT01582945
Completed
Ketamine infusion has been shown to have rapid antidepressant properties, however the possible use of ketamine in treatment-resistant depression as augmentation has not been investigated. The overall aim of this study is to assess the feasibility, safety and tolerability, efficacy and duration of the effect of intravenous N-methyl-D-aspartate antagonist ketamine as augmentation of antidepressants for chronic suicidal ideation in subjects with severe treatment-resistant depression (TRD). This is... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2017
Locations: Depression Clinical and Research Program - MGH, Boston, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates
Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder
NCT01667926
Completed
Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous administration of ketamine in severely depressed, treatment resistant patients. The results of the study could lead to development of new strategies for treating depression.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2017
Locations: Depression Clinical and Reseach Program - MGH, Boston, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates